Preventing Arteriovenous Shunt Failure in Hemodialysis Patients: A Population ‐Based Cohort Study
ConclusionAntiplatelet agents but not wafarin might reduce the vascular access thrombosis rate.The gastrointestinal bleeding rate was increased in the group using clopidogrel. Aggrenox should be used with caution in young individuals since it might increase the rate of intracerebral hemorrhage.This article is protected by copyright. All rights reserved. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - November 25, 2018 Category: Hematology Authors: Pei Yi Fan, Cheng Chia Lee, Shou Hsuan Liu, I ‐Jung Li, Cheng Hao Weng, Kun Hua Tu, Mei Yun Hsieh, Chang Fu Kuo, Ting‐Yu Chang, Ya Chung Tian, Chih Wei Yang, Hsin Hsu Wu Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Preventing Arteriovenous Shunt Failure in Hemodialysis Patients: A Population-Based Cohort Study.
CONCLUSION: Antiplatelet agents but not wafarin might reduce the vascular access thrombosis rate. The gastrointestinal bleeding rate was increased in the group using clopidogrel. Aggrenox should be used with caution in young individuals since it might increase the rate of intracerebral hemorrhage. This article is protected by copyright. All rights reserved. PMID: 30472783 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - November 25, 2018 Category: Hematology Authors: Fan PY, Lee CC, Liu SH, Li IJ, Weng CH, Tu KH, Hsieh MY, Kuo CF, Chang TY, Tian YC, Yang CW, Wu HH Tags: J Thromb Haemost Source Type: research

Oral Dipyridamole-Associated Circulatory Collapse
Extended-release dipyridamole plus aspirin is widely used for secondary prevention of ischemic stroke, although the molecular pharmacodynamics of dipyridamole are not completely determined. Adverse effects of fixed-dose combination of aspirin and dipyridamole include headache, bleeding, and gastrointestinal events. Previously, intravenous infusion of dipyridamole in cardiac stress testing has been associated with cardiogenic shock and pulmonary edema. Herein, we report a case study of a 72-year-old man, presented with a transient ischemic attack who suffered a circulatory collapse after an oral dose of 200 mg extended-rele...
Source: Journal of Stroke and Cerebrovascular Diseases - September 2, 2018 Category: Neurology Authors: Pasi Jolma, Jyrki Ollikainen, Ilkka Uurto Source Type: research

O-026 Prior antiplatelet use and thrombectomy outcomes
Conclusion Prior use of APT drug is associated with higher rates of successful recanalization in ELVO patients after MT, however no difference in rates of sICH or functional outcome was noted. Larger studies are needed to further evaluate the role of prior treatment with APT drug in ELVO patients treated with MT. Disclosures A. Pandhi: None. R. Krishnan: None. K. Dillard: None. M. Ishfaq: None. S. Singh: None. D. Hoit: None. A. Arthur: None. G. Tsivgoulis: None. A. Alexandrov: None. L. Elijovich: None. N. Goyal: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 23, 2017 Category: Neurosurgery Authors: Pandhi, , Krishnan, R., Dillard, K., Ishfaq, M., Singh, S., Hoit, D., Arthur, A., Tsivgoulis, G., Alexandrov, A., Elijovich, L., Goyal, N. Tags: Oral Abstracts Source Type: research

Antiplatelet Strategies for Secondary Prevention of Stroke and TIA
Abstract Stroke is a major public health issue, and stroke recurrence accounts for a quarter of all events. Antiplatelet therapy has been extensively studied for secondary stroke prevention and is established as effective in this high-risk population. Several agents have been evaluated in this setting, both in isolation and combination. The most widely used antiplatelet medications are aspirin, clopidogrel, and aspirin plus extended-release dipyridamole. However, new agents and combinations continue to be evaluated. A detailed review of the evidence supporting various antiplatelet regimens for secondary stroke pr...
Source: Current Atherosclerosis Reports - September 10, 2014 Category: Cardiology Source Type: research

Meta-analysis finds benefit for dual antiplatelet therapy but limitations preclude changing standard mono antiplatelet therapy approach for acute non-cardioembolic ischaemic stroke or transient ischaemic attack
Commentary on: Wong KSL, Wang Y, Leng X, et al.. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack. An updated systematic review and meta-analysis. Circulation 2013;128:1656–66. Context Current guidelines recommend aspirin, aspirin plus clopidogrel or aspirin plus extended-release dipyridamole for treatment of acute ischaemic stroke (IS) or transient ischaemic attack (TIA) to prevent recurrent stroke, myocardial infarction and cardiovascular death.1 The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial ra...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Aronow, W. S. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease Therapeutics Source Type: research

Spray Drying as a Fast and Simple Technique for the Preparation of Extended Release Dipyridamole (DYP) Microparticles in a Fixed Dose Combination (FDC) Product with Aspirin
Drug Res (Stuttg)DOI: 10.1055/s-0033-1361119© Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents  |  Full text (Source: Drug Research)
Source: Drug Research - November 18, 2013 Category: Drugs & Pharmacology Authors: Hamishehkar, H.Valizadeh, H.Alasty, P.Monajjemzadeh, F. Tags: Erratum Source Type: research